Chris Polman
Overview
Explore the profile of Chris Polman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
3148
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wattjes M, Rovira A, Miller D, Yousry T, Sormani M, de Stefano M, et al.
Nat Rev Neurol
. 2015 Sep;
11(10):597-606.
PMID: 26369511
The role of MRI in the assessment of multiple sclerosis (MS) goes far beyond the diagnostic process. MRI techniques can be used as regular monitoring to help stage patients with...
2.
Rovira A, Wattjes M, Tintore M, Tur C, Yousry T, Sormani M, et al.
Nat Rev Neurol
. 2015 Jul;
11(8):471-82.
PMID: 26149978
The clinical use of MRI in patients with multiple sclerosis (MS) has advanced markedly over the past few years. Technical improvements and continuously emerging data from clinical trials and observational...
3.
Kappos L, OConnor P, Radue E, Polman C, Hohlfeld R, Selmaj K, et al.
Neurology
. 2015 Mar;
84(15):1582-91.
PMID: 25795646
Objective: To assess long-term safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (RRMS). Methods: Patients completing FTY720 Research Evaluating Effects of Daily Oral Therapy in MS (FREEDOMS)...
4.
Kontschieder P, Dorn J, Morrison C, Corish R, Zikic D, Sellen A, et al.
Med Image Comput Comput Assist Interv
. 2014 Dec;
17(Pt 2):429-37.
PMID: 25485408
This paper presents new learning-based techniques for measuring disease progression in Multiple Sclerosis (MS) patients. Our system aims to augment conventional neurological examinations by adding quantitative evidence of disease progression....
5.
Cohen J, Krishnan A, Goodman A, Potts J, Wang P, Havrdova E, et al.
JAMA Neurol
. 2014 Sep;
71(11):1386-93.
PMID: 25178496
Importance: Walking impairment, a common clinical manifestation of multiple sclerosis (MS), is often measured in clinical practice and clinical trials using the Timed 25-Foot Walk (T25-FW). Objective: To evaluate the...
6.
OConnor P, Goodman A, Kappos L, Lublin F, Polman C, Rudick R, et al.
Neurology
. 2014 Jun;
83(1):78-86.
PMID: 24898925
Objectives: Report long-term safety and effectiveness of natalizumab over 240 weeks in the prospective, observational, open-label Safety of TYSABRI Re-dosing and Treatment (STRATA) Study. Methods: Patients (N = 1,094) previously...
7.
Mitjana R, Tintore M, Rocca M, Auger C, Barkhof F, Filippi M, et al.
Mult Scler
. 2014 Mar;
20(11):1471-7.
PMID: 24576831
Background: Non-enhancing black holes (neBHs) are more common in multiple sclerosis (MS) patients with longer disease durations and progressive disease subtypes. Objective: Our aim was to analyse the added value...
8.
Progression in disability and regional grey matter atrophy in relapsing-remitting multiple sclerosis
Hofstetter L, Naegelin Y, Filli L, Kuster P, Traud S, Smieskova R, et al.
Mult Scler
. 2013 Jun;
20(2):202-13.
PMID: 23804554
Background: In multiple sclerosis (MS) regional grey matter (GM) atrophy has been associated with disability progression. Objective: The aim of this study was to compare regional GM volume changes in...
9.
Rudick R, Polman C, Clifford D, Miller D, Steinman L
JAMA Neurol
. 2012 Nov;
70(2):172-82.
PMID: 23128399
Natalizumab has been available as a multiple sclerosis treatment for more than 5 years in Europe and the United States. Natalizumab was granted approval by the US Food and Drug...
10.
Filli L, Hofstetter L, Kuster P, Traud S, Mueller-Lenke N, Naegelin Y, et al.
Mult Scler
. 2012 Apr;
18(11):1577-84.
PMID: 22495945
Background: Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. MS lesions show a typical distribution pattern and primarily affect the white matter (WM) in the...